Filing Flows › Aurinia Pharmaceuticals (AUPH) › Guidance & outlook
Aurinia Pharmaceuticals (AUPH) guidance and outlook
Aurinia Pharmaceuticals (AUPH) raised its guidance on Oct 30, 2026: Revenue $325M–$330M for FY2026. Aurinia Pharmaceuticals' 10-Q filed Oct 30, 2026 makes 5 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $325M–$330M | raised |
From the earnings release filed Oct 30, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Oct 30, 2026
- We continue to expect our SG&A expense to remain substantially consistent.
- We expect our R&D expense to increase as we progress our development activities.
- Based on our current operating plans and projections, the Company expects to fund future operations with existing cash or cash flows from operating activities.
- If necessary, we intend to raise additional capital through equity or debt financings.
- We can provide no assurance that additional financing will be available to us on favorable terms, or at all.
Aurinia Pharmaceuticals' latest quarter
Aurinia Pharmaceuticals, Q3 2026: revenue $83.7M (+14% year over year), operating margin 42.3%, net earnings $31.7M, operating cash flow $46.4M. The chart follows the revenue to costs, profit and cash.
Questions
Did Aurinia Pharmaceuticals raise or lower its guidance?
Aurinia Pharmaceuticals (AUPH) raised its guidance on Oct 30, 2026: Revenue $325M–$330M for FY2026.
What does Aurinia Pharmaceuticals expect?
We continue to expect our SG&A expense to remain substantially consistent. We expect our R&D expense to increase as we progress our development activities. Based on our current operating plans and projections, the Company expects to fund future operations with existing cash or cash flows from operating activities.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.